← Back
Data updated: Mar 10, 2026
NEXUS
MetabolicInfectious DiseaseOncology
NEXUS is a generic drug manufacturer focused on Metabolic, Infectious Disease, Oncology. Key products include CYCLOPHOSPHAMIDE.
2004
Since
27
Drugs
-
Trials
142
Approved (2yr)
Key Drugs
Recent Activity
METHYLENE BLUE 2026-02-02
Manufacturing (CMC)
ARSENIC TRIOXIDE 2026-01-30
Labeling
TRANEXAMIC ACID 2026-01-26
METHYLENE BLUE 2025-12-23
POTASSIUM CHLORIDE 2025-12-22
ISOPROTERENOL HYDROCHLORIDE 2025-12-10
POTASSIUM CHLORIDE 2025-11-20
NELARABINE 2025-11-06
Labeling
POTASSIUM CHLORIDE 2025-10-27
Labeling
TACROLIMUS 2025-10-17
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Metabolic 32%
3 drugs
Infectious Disease 21%
2 drugs
Oncology 21%
2 drugs
Neurology 16%
1 drugs Phase 2: 1 Phase 1: 1
Dermatology 11%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Eli Lilly big-pharma
Metabolic, Oncology, Neurology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Infectious Disease, Neurology
Active (17)
METHYLENE BLUE FLUORESCEIN SODIUM NELARABINE TIROFIBAN HYDROCHLORIDE POTASSIUM CHLORIDE 20MEQ POTASSIUM CHLORIDE 10MEQ POTASSIUM CHLORIDE 40MEQ EMERPHED LEVETIRACETAM IN SODIUM CHLORIDE TRANEXAMIC ACID TACROLIMUS COLISTIMETHATE SODIUM ERYTHROMYCIN LACTOBIONATE CYCLOPHOSPHAMIDE STERILE WATER FOR INJECTION TESTOSTERONE ENANTHATE SUCCINYLCHOLINE CHLORIDE
Discontinued (10)
Company Info
- First Approval
- 2004-03-19
- Latest
- 2025-07-11
- Applications
- 25